CD39 Molecule Information
Name:Ectonucleoside triphosphate diphosphohydrolase 1
Target Synonym:ENTPD1;Ecto-ATPDase 1;CD39;Ecto-ATPase 1;NTPDase 1;Ectonucleoside triphosphate diphosphohydrolase 1;CD_antigen=CD39;Ecto-ATP diphosphohydrolase 1;Ecto-apyrase;Lymphoid cell activation antigen
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase ?
CD39 Molecule Synonym Name
CD39,ENTPD1,NTPDase 1,Entpd1,Ecto-ATPDase 1,Ecto-ATPase 1
CD39 Molecule Background
CD39 is also known as Ectonucleoside triphosphate diphosphohydrolase 1, ENTPD1, NTPDase 1, Ecto-ATPDase 1, in the nervous system, could hydrolyze ATP and other nucleotides to regulate purinergic neurotransmission. Could also be implicated in the prevention of platelet aggregation by hydrolyzing platelet-activating ADP to AMP. Hydrolyzes ATP and ADP equally well. NTPDase-1 was originally described as CD39, a B lymphocyte cell surface marker, but it is also present on the surface of natural killer cells, T cells, and some endothelial cells.Regulatory T cells(Tregs) mediate immunosuppression through multiple, non-redundant, cell-contact dependent and independent mechanisms, a growing body of evidence suggests an important role for the CD39-CD73-adenosine pathway. CD39 ectonucleotidase is the rate-limiting enzyme of a cascade leading to the generation of suppressive adenosine that alters CD4 and CD8 T cell and natural killer cell antitumor activities.
CD39 Clinical Drug Information
||INSERM, Orega Biotech, AstraZeneca, Innate
||Advanced solid tumors
||Tizona Therapeutics, Abbvie